ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2026
Renal risk differences between diffuse large B-cell lymphoma and chronic lymphocytic leukemia/small lymphocytic lymphoma: implications for supportive oncology care.
Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDiffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) differ markedly in disease biology and treatment intensity, yet comparative renal outcome data are limited. We compared acute kidney injury (AKI) and chronic kidney disease (CKD) incidence between demographically matched DLBCL and CLL/SLL cohorts.
methodsRetrospective cohort study using the TriNetX Global Collaborative Network (143 healthcare organizations; data extracted May 9, 2025). Adults with DLBCL (ICD-10 C83.3) or CLL/SLL (C91.1, C83.0) underwent 1:1 propensity score matching for age, sex, race, and ethnicity. AKI (N17) and CKD (N18) were assessed from day 1 post-index through each patient's available follow-up (an open-ended window; no fixed follow-up duration was generated). Risk differences, risk ratios, and odds ratios (ORs) with 95% CIs were calculated using two-proportion z-tests.
resultsAfter matching, 19,438 patients (9719/cohort) were analyzed. AKI occurred in 22.9% of DLBCL versus 20.9% of CLL/SLL patients (risk difference 2.0%, 95% CI 0.8-3.1%; risk ratio 1.094, 95% CI 1.037-1.154; OR 1.122, 95% CI 1.048-1.201, p = 0.001). CKD occurred in 18.8% of DLBCL versus 22.7% of CLL/SLL patients (risk difference -4.0%, 95% CI -5.1 to -2.8%; risk ratio 0.825, 95% CI 0.781-0.872; OR 0.785, 95% CI 0.732-0.842, p < 0.001). Demographic characteristics were well balanced (SMD 0.001-0.038). Comorbidities and follow-up duration were not captured by this matching algorithm and are addressed as limitations.
conclusionDLBCL showed modestly higher AKI risk and CLL/SLL showed modestly higher CKD burden in this demographically matched cohort. Because comorbidities were not matched and absolute differences were small, these findings are hypothesis-generating, supporting attention to renal monitoring in both subtypes pending comorbidity-adjusted, prospective confirmation.
Indexed as
Identifiers
42806171What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.